These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 39067250

  • 1. Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis.
    Li B, Tan S, Yu X, Wang Y.
    Biochem Biophys Res Commun; 2024 Nov 12; 733():150440. PubMed ID: 39067250
    [Abstract] [Full Text] [Related]

  • 2. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X, Xiao XY, Shou QY, Yan JF, Chen L, Fu HY, Wang JC.
    J Ethnopharmacol; 2016 Dec 04; 193():538-545. PubMed ID: 27686271
    [Abstract] [Full Text] [Related]

  • 3. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P, Song H.
    Cell Physiol Biochem; 2018 Dec 04; 48(4):1505-1518. PubMed ID: 30071534
    [Abstract] [Full Text] [Related]

  • 4. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L, Zhang B, Li W.
    Mol Med Rep; 2021 Apr 04; 23(4):. PubMed ID: 33576437
    [Abstract] [Full Text] [Related]

  • 5. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S, Tan W, Du B, Liu W, Li W, Che D, Zhang G.
    Mol Med Rep; 2016 Apr 04; 13(4):3342-8. PubMed ID: 26935490
    [Abstract] [Full Text] [Related]

  • 6. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
    Su S, Dou H, Wang Z, Zhang Q.
    Basic Clin Pharmacol Toxicol; 2021 Feb 04; 128(2):224-233. PubMed ID: 32905663
    [Abstract] [Full Text] [Related]

  • 7. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM.
    Chemotherapy; 2019 Feb 04; 64(3):119-128. PubMed ID: 31661694
    [Abstract] [Full Text] [Related]

  • 8. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C, Wang M, Shi C, Shi F, Pei C.
    Biosci Trends; 2018 Jul 17; 12(3):309-316. PubMed ID: 29952351
    [Abstract] [Full Text] [Related]

  • 9. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY, Li N, Cui YL.
    Cancer Res Treat; 2020 Jul 17; 52(3):798-814. PubMed ID: 32124583
    [Abstract] [Full Text] [Related]

  • 10. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
    Wang H, Luo Y, Qiao T, Wu Z, Huang Z.
    J Ovarian Res; 2018 Nov 19; 11(1):93. PubMed ID: 30454003
    [Abstract] [Full Text] [Related]

  • 11. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
    Zhang J, Bai HJ.
    Zhonghua Zhong Liu Za Zhi; 2021 Oct 23; 43(10):1062-1068. PubMed ID: 34695896
    [Abstract] [Full Text] [Related]

  • 12. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P, Hu Y, Qu P, Zhao Y, Liu J, Zhao J, Kong B.
    Bioengineered; 2022 Jan 23; 13(1):1931-1941. PubMed ID: 35001804
    [Abstract] [Full Text] [Related]

  • 13. Tasquinimod enhances the sensitivity of ovarian cancer cells to cisplatin by regulating the Nur77-Bcl-2 apoptotic pathway.
    Lin Y, Liu YQ, Zhu KA, Hu MQ, Li Z, Min XJ.
    Adv Clin Exp Med; 2024 Feb 23; 33(2):151-161. PubMed ID: 37501511
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q, Zhang Y, Wang Z, Ding J, Song Y, Zhao W.
    Clin Exp Immunol; 2020 Apr 23; 200(1):45-52. PubMed ID: 31821542
    [Abstract] [Full Text] [Related]

  • 15. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
    Gong S, Chen Y, Meng F, Zhang Y, Li C, Zhang G, Huan W, Wu F.
    Cell Prolif; 2018 Oct 23; 51(5):e12474. PubMed ID: 30069985
    [Abstract] [Full Text] [Related]

  • 16. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y, Peng YB, Ye LL, Ma LX, Zou MY, Cheng ZG.
    Mol Med Rep; 2020 Mar 23; 21(3):1471-1480. PubMed ID: 32016462
    [Abstract] [Full Text] [Related]

  • 17. Cinobufotalin regulates the USP36/c-Myc axis to suppress malignant phenotypes of colon cancer cells in vitro and in vivo.
    Hu Y, Luo M.
    Aging (Albany NY); 2024 Mar 15; 16(6):5526-5544. PubMed ID: 38517383
    [Abstract] [Full Text] [Related]

  • 18. The anthraquinone derivative KA-4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin.
    Zhao Y, Li X, Xu S, Yang Y, Chen Q, Li J, Tian W, Zhang Q, Hou H, Li D.
    Mol Carcinog; 2024 Nov 15; 63(11):2090-2102. PubMed ID: 39092774
    [Abstract] [Full Text] [Related]

  • 19. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J, Wang Q, Zhang W, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr 25; 51(4):285-92. PubMed ID: 27116987
    [Abstract] [Full Text] [Related]

  • 20. Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells.
    Zhao H, Zhao D, Jin H, Li H, Yang X, Zhuang L, Liu T.
    Mol Med Rep; 2016 Aug 25; 14(2):1817-22. PubMed ID: 27357249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.